PI3K/AKT/mTOR Pathway in Angiogenesis

Abstract

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is activated in the majority of human cancers. This pathway is known to play a key role in numerous cellular functions including proliferation, adhesion, migration, invasion, metabolism, and survival, but in the current review we focus on its role in angiogenesis. PI3K activation may occur via RAS mutation, loss of phosphatase and tensin homolog (PTEN), or by increased expression of growth factor receptors such as epidermal growth factor receptor. There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to HIF-1α stabilization and is a major stimulus for increased vascular endothelial growth factor (VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) dependent and independent mechanisms. The PI3K/AKT pathway also modulates the expression of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on tumor vasculature can be difficult to predict. The vasculature of tumors is aberrant, leading to sluggish bloodflow and elevated interstitial blood pressure, which can be perpetuated by the high levels of VEGF. Hence, decreasing VEGF expression can paradoxically lead to vascular normalization and improved bloodflow in some tumors. In addition to its importance in cancer, the PI3K pathway also plays an essential role in the formation of normal blood vessels during development. Embryos with kinase-dead p110α catalytic subunit of PI3K develop vascular defects. Stimulation of endothelial cells by VEGF leads to activation of the PI3K pathway within these cells, which is important for cell migration. Sustained endothelial activation of AKT1 has been shown to induce the formation of structurally abnormal blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway plays an important role in regulating angiogenesis both in normal tissues and in cancers.

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

“…In addition to effects on cell growth, the mTOR pathway also plays a role in angiogenesis (23). Our in vivo mechanistic study assessing blood vessel density by anti-CD-31 (24), shows CC-223 treatment results in a significant reduction in tumor vascularization.…”

Inhibition of MicroRNA‐155 Supports Endothelial Tight Junction Integrity Following Oxygen‐Glucose Deprivation

“…SMAD‐1 is a member of the bone morphogenetic protein pathway, implicated in vascular stabilization 48. Increased expression of Rictor, a major component of the mTORC2 complex, could activate mTOR signaling, which plays an important role in endothelial cell function 49, 50…”

Human adipose-derived mesenchymal stem cell could participate in angiogenesis in a mouse model of acute hindlimb ischemia

“…VEGF binding stimulated proliferation and decreased apoptosis of endothelial cells, leading to the increased efficiency of ischemic hindlimb treatment. In addition, VEGF prevents apoptosis through phosphatidylinositol (PI)-3-kinase Akt pathway or through the stimulation of antiapoptosis Bcl-2 and A1 factors production in endothelial cells (Karar and Maity, 2011;Xiao et al, 2014). PI-3-kinase Akt pathway activates vascular growth factors such as eNOS and HIF-1α.…”